Method of treatment of hemorrhagic disease using a factor VIIa/tissue factor inhibitor
First Claim
1. A method of treating a mammal having a hemorrhagic fever which comprises administering to said mammal an amount of a selective Factor VIIa/tissue factor inhibitor effective to ameliorate symptoms of said fever.
9 Assignments
0 Petitions
Accused Products
Abstract
The present invention provides methods of treating hemorrhagic fevers where selective inhibitors of fVIIa/TF are used as a treatment for hemorrhagic fevers and have therapeutic effects which include ameliorating and/or preventing coagulopathy and inflammatory responses. These inhibitors include certain proteins which are part of a family termed Nematode-Extracted Anticoagulant Proteins (“NAPs”). Other inhibitors include Tissue Factor Pathway Inhibitor (“TFPI”) and TFPI analogs.
-
Citations
27 Claims
- 1. A method of treating a mammal having a hemorrhagic fever which comprises administering to said mammal an amount of a selective Factor VIIa/tissue factor inhibitor effective to ameliorate symptoms of said fever.
-
10. A method of treating a mammal having a hemorrhagic fever which comprises administering to said mammal a therapeutically effective amount of a compound which specifically inhibits the catalytic activity of the fVIIa/TF complex in the presence of Factor Xa (“
- fXa”
) or catalytically inactive fXa derivative and does not specifically inhibit the catalytic activity of the fVIIa/TF complex in the absence of fXa or catalytically inactive fXa derivative and does not specifically inhibit the activity of fVIIa in the absence of the TF and does not specifically inhibit prothrombinase. - View Dependent Claims (11, 12, 13, 14, 15, 16, 17, 18)
- fXa”
- 19. A method of treating coagulopathy and/or an inflammatory response due to a hemorrhagic fever in a mammal which comprises administering to said mammal an amount of a selective fVIIa/TF inhibitor effective to decrease or prevent said coagulopathy and/or inflammatory response in said mammal.
Specification